These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 6292093

  • 21. Stimulation with allogeneic Epstein-Barr virus-transformed lymphoblastoid cell lines generates HLA class I-specific CTLs with different target cell avidity.
    Torsteinsdottir S, Cuomo L, Klein E, Masucci MG.
    Cell Immunol; 1991 Oct 15; 137(2):501-13. PubMed ID: 1654213
    [Abstract] [Full Text] [Related]

  • 22. The effect of tinidazole on primary EBV infection and immunocompetence.
    Marklund G, Ernberg I, Britton S, Lundberg C.
    Scand J Infect Dis; 1984 Oct 15; 16(1):17-23. PubMed ID: 6320359
    [Abstract] [Full Text] [Related]

  • 23. Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis.
    Tomkinson BE, Maziarz R, Sullivan JL.
    J Immunol; 1989 Jul 15; 143(2):660-70. PubMed ID: 2472449
    [Abstract] [Full Text] [Related]

  • 24. Cytotoxic mechanisms in vitro against Epstein-Barr virus infected lymphoblastoid cell lines in rheumatoid arthritis.
    McChesney MB, Bankhurst AD.
    Ann Rheum Dis; 1986 Jul 15; 45(7):546-52. PubMed ID: 3017244
    [Abstract] [Full Text] [Related]

  • 25. Mitotic EBNA-positive lymphocytes in peripheral blood during infectious mononucleosis.
    Robinson J, Smith D, Niederman J.
    Nature; 1980 Sep 25; 287(5780):334-5. PubMed ID: 6252472
    [Abstract] [Full Text] [Related]

  • 26. Antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus-determined membrane antigens. I. Reactivity in sera from normal persons and from patients with acute infectious mononucleosis.
    Jondal M.
    Clin Exp Immunol; 1976 Jul 25; 25(1):1-5. PubMed ID: 186222
    [Abstract] [Full Text] [Related]

  • 27. Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. III. Establishment of HLA-restricted cytotoxic T cell lines using interleukin 2.
    Wallace LE, Rowe M, Gaston JS, Rickinson AB, Epstein MA.
    Eur J Immunol; 1982 Dec 25; 12(12):1012-8. PubMed ID: 6297919
    [Abstract] [Full Text] [Related]

  • 28. The MLC response of patients with infectious mononucleosis to Epstein-Barr virus-transformed cells.
    Wasik M, Myc A, Matej H, Rudzka L.
    Arch Immunol Ther Exp (Warsz); 1983 Dec 25; 31(6):871-8. PubMed ID: 6331340
    [Abstract] [Full Text] [Related]

  • 29. Infectious mononucleosis complicated by transitory Epstein-Barr virus infection of T and natural killer cells.
    Zhang Y, Xie J, Zheng Y, Zhou X.
    J Hematop; 2024 Sep 25; 17(3):129-137. PubMed ID: 38967898
    [Abstract] [Full Text] [Related]

  • 30. Absence of allogeneic restriction in human T-cell-mediated cytotoxicity to Epstein-Barr virus-infected target cells. Demonstration of an HLA-linked control at the effector level.
    Lipinski M, Fridman WH, Tursz T, Vincent C, Pious D, Fellous M.
    J Exp Med; 1979 Dec 01; 150(6):1310-22. PubMed ID: 229186
    [Abstract] [Full Text] [Related]

  • 31. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.
    Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K.
    Cancer Sci; 2008 Aug 01; 99(8):1633-42. PubMed ID: 18754877
    [Abstract] [Full Text] [Related]

  • 32. Composite response of naive T cells to stimulation with the autologous lymphoblastoid cell line is mediated by CD4 cytotoxic T cell clones and includes an Epstein-Barr virus-specific component.
    Misko IS, Sculley TB, Schmidt C, Moss DJ, Soszynski T, Burman K.
    Cell Immunol; 1991 Feb 01; 132(2):295-307. PubMed ID: 1846323
    [Abstract] [Full Text] [Related]

  • 33. [Virological and immunological studies on inapparent Epstein-Barr virus infection in healthy individuals: in comparison to immunosuppressed patients and patients with infectious mononucleosis].
    Imai S.
    Hokkaido Igaku Zasshi; 1990 Sep 01; 65(5):481-92. PubMed ID: 2172132
    [Abstract] [Full Text] [Related]

  • 34. Epstein-Barr virus: a human pathogen inducing lymphoproliferation in vivo and in vitro.
    Sugden B.
    Rev Infect Dis; 1982 Sep 01; 4(5):1048-61. PubMed ID: 6293034
    [Abstract] [Full Text] [Related]

  • 35. Defective killer cell activity in patients with chronic active Epstein-Barr virus infection.
    Wakiguchi H, Fujieda M, Matsumoto K, Ohara Y, Wakiguchi A, Kurashige T.
    Acta Med Okayama; 1988 Jun 01; 42(3):137-42. PubMed ID: 2840801
    [Abstract] [Full Text] [Related]

  • 36. Stimulation of normal lymphocytes with autologous lymphoid cell lines: properties of derived killer cells.
    Svedmyr E, Jondal M, Leibold W.
    Scand J Immunol; 1975 Jun 01; 4(7):721-34. PubMed ID: 173017
    [Abstract] [Full Text] [Related]

  • 37. Human cytotoxic T lymphocytes (CTL) against Epstein-Barr virus (EBV) infected cells: EBV specificity and involvement of major histocompatibility complex determinants in the lysis exerted by anti-EBV CTL toward HLA-compatible and allogeneic target cells.
    Lakhdar M, Senik A, Fridman WH.
    Cell Immunol; 1984 Feb 01; 83(2):414-21. PubMed ID: 6198104
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. I. Specificity and HLA restriction of effector cells reactivated in vitro.
    Moss DJ, Wallace LE, Rickinson AB, Epstein MA.
    Eur J Immunol; 1981 Sep 01; 11(9):686-93. PubMed ID: 6170517
    [Abstract] [Full Text] [Related]

  • 40. Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis).
    Tosato G, Straus S, Henle W, Pike SE, Blaese RM.
    J Immunol; 1985 May 01; 134(5):3082-8. PubMed ID: 2984282
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.